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Multiple cornerstones have shaped the history of vaccines, which may contain live-
attenuated viruses, inactivated organisms/viruses, inactivated toxins, or merely segments
of the pathogen that could elicit an immune response. The story began with Hippocrates
400 B.C. with his description of mumps and diphtheria. No further discoveries were
recorded until 1100 A.D. when the smallpox vaccine was described. During the eighteenth
century, vaccines for cholera and yellow fever were reported and Edward Jenner, the
father of vaccination and immunology, published his work on smallpox. The nineteenth
century was a major landmark, with the “Germ Theory of disease” of Louis Pasteur,
the discovery of the germ tubercle bacillus for tuberculosis by Robert Koch, and the
isolation of pneumococcus organism by George Miller Sternberg. Another landmark was
the discovery of diphtheria toxin by Emile Roux and its serological treatment by Emil
Von Behring and Paul Ehrlih. In addition, Pasteur was able to generate the first live-
attenuated viral vaccine against rabies. Typhoid vaccines were then developed, followed
by the plague vaccine of Yersin. At the beginning of World War I, the tetanus toxoid was
introduced, followed in 1915 by the pertussis vaccine. In 1974, The Expanded Program of
Immunization was established within the WHO for bacille Calmette–Guerin, Polio, DTP,
measles, yellow fever, and hepatitis B. The year 1996 witnessed the launching of the
International AIDS Vaccine Initiative. In 1988, the WHO passed a resolution to eradicate
polio by the year 2000 and in 2006; the first vaccine to prevent cervical cancer was
developed. In 2010, “The Decade of vaccines” was launched, and on April 1st 2012,
the United Nations launched the “shot@Life” campaign. In brief, the armamentarium of
vaccines continues to grow with more emphasis on safety, availability, and accessibility.
This mini review highlights the major historical events and pioneers in the course of
development of vaccines, which have eradicated so many life-threatening diseases,
despite the vaccination attitudes and waves appearing through history.
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INTRODUCTION
Vaccines constitute one of the greatest success stories within the health sector. They form part of a
multifaceted public health response to the emergence of pandemics. This review is general in nature.
It highlights the major historical cornerstones in the development and progress of various types of
vaccines since the beginning and through the ages until today.
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It recognizes the major pioneers whose work has made a dif-
ference in the advancement of this vital health field, despite all
the anti-vaccination movements that appeared through the ages.
Multiple reviews were encountered during our literature search;
however, each of those reviews dealt with a specific aspect of
vaccination like effectiveness of a particular vaccine, or side effects
of another or even attitudes toward vaccines. Consequently, this
work tried to put together themajor achievements through history
stressing the importance, continuous vital role, and the need for
immunization for health prevention and protection as well as its
impact on human experience.
The physiological mechanisms behind vaccination are well
established. Vaccination activates the immune system and induces
both innate and adaptive immune responses thus leading to the
production of antibodies, in the case of a humoral response, or
to the generation of memory cells that will recognize the same
antigen, if there is a later exposure. Periodic repeat injections can
improve the efficacy and effectiveness of inoculations (1).
The approval of a vaccine abides by a set of well-established
international rules and regulations. Prior to their approval by the
respective health authorities, scientists test vaccines extensively
in order to ensure their efficacy, safety, and effectiveness. Next
to antibiotics, vaccines are the best defense that we have to date
against infectious diseases; however, no vaccine is actually 100%
safe or effective for everyone. This is attributed to the fact that
each body reacts to vaccines differently (2–4). Significant progress
has been made over the years to monitor side effects and conduct
research relevant to vaccine safety. In addition, vaccine licensing
is a lengthy process that may take 10 years or longer. The Food
and Drug Administration (FDA) and the National Institute of
Health (NIH) require that vaccines undergo the required phases
of clinical trials on human subjects prior to any use in the gen-
eral public. This process is becoming more complex as more
caution and care is being allocated to the quality of the market
product.
Furthermore, vaccines can be divided into different categories
depending on the way that they are prepared including live-
attenuated vaccines, inactivated vaccines, subunit vaccines, con-
jugate vaccines, and toxoids.
LIVE-ATTENUATED VACCINES
Live-attenuated vaccines are used more frequently for viruses
rather than bacteria, since the former contain a lesser amount of
genes and can be controlled more easily (5). The most common
method in formulating live-attenuated vaccines involves pass-
ing the virus through successions of cell cultures to weaken it.
This will produce a form of the virus that is no longer able
to replicate in human cells. However, it will still be recognized
by the human immune system, hence protecting the body from
future invasions. Examples of such vaccines are measles, rubella,
mumps, varicella (more commonly known as chickenpox), and
influenza. The disadvantage of using this technique is that the
virus may transform into a more virulent form due to a cer-
tain mutation and cause illness once injected into the body.
Although this rarely occurs, it must always be taken into consid-
eration (6).
INACTIVATED VACCINES
By using heat, radiation, or certain chemicals, one can inactivate
a microbe. The microbe will no longer cause illness but can still
be recognized by the immune system. Poliovirus and Hepati-
tis A are common examples of inactivated vaccines. This type
of vaccine has the disadvantage of being effective for a shorter
period of time than live-attenuated vaccines. Multiple boosters of
the vaccine are sometimes required to improve effectiveness and
sustainability (6).
SUBUNIT VACCINES
A subunit vaccine contains only portions of the microbe that can
be presented as antigens to the human immune system instead
of the microbe as a whole. The antigens or the microbe portions
that best activate the immune response are usually selected. An
influenza vaccine in the form of shots is an example. In addition,
a recombinant subunit vaccine has been made for the hepatitis B
virus. Hepatitis B genes are injected into maker cells in culture.
Once these cells reproduce, the desired antigens of the virus are
produced as well, and these can be purified for use in vaccines (6).
CONJUGATE VACCINES
Conjugate vaccines are designed from parts of the bacterial coat.
However, these parts may not produce an effective immune
response when presented alone. Hence, they are combined with
a carrier protein. These carrier proteins are chemically linked
to the bacterial coat derivatives. Together, they generate a more
potent response and can protect the body against future infections.
Vaccines against pneumococcal bacteria used in children are an
example of conjugate vaccines (6).
TOXOIDS
Some bacteria release harmful toxins that cause illness in infected
individuals. Vaccinations against such types of bacteria are pre-
pared by inactivating or weakening the toxin using heat or certain
chemicals. This will help prepare the immune system against
future invasion. The vaccine against tetanus caused by the neu-
rotoxin of Clostridium tetani is a good example of a toxoid (6).
VACCINATION: ITS DETERMINANTS AND
MODULATION WITH AGE
The generation of vaccine-mediated protection is a complex chal-
lenge. Effective early protection is conferred primarily by the
induction of antigen-specific antibodies. The quality of such anti-
body responses has been identified as a determining factor of
efficacy. Efficacy requires long-term protection, namely, the per-
sistence of vaccine antibodies and/or the generation of immune
memory cells capable of rapid and effective reactivation upon
subsequent microbial exposure (7).
The exponential development of new vaccines raises many
questions about their impact on the immune system. Such ques-
tions related to immunological safety of vaccines as well as trigger-
ing conditions such as allergy, autoimmunity, or even premature
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death (7). Such issues were always looked for and monitored and
some vaccines were even stopped because of these issues.
Recent vaccine models rely on both a cell-mediated response
and a humoral immune response with highly specific antibodies
and have shown an adequate amount of success. This, however,
has not been the case for a few diseases such as tuberculosis where
the humoral immunity mounted by the bacille Calmette–Guerin
(BCG), the only currently used human vaccine, is inefficient in
conferring proper immunization (8). However, T cells do take
part indirectly in the production of antibodies and of secreted
biological molecules (e.g., Interferon) for protection. It seems
that a proper mounted immunity is better achieved by vaccine-
induced antibodies, whereas a T cell immune response is needed
for disease attenuation. Hence, a robust understanding of B and
T cell function is needed for proper immunization (9).
Multiple determinants modulate the primary vaccine antibody
response in healthy individuals; they include the vaccine type,
live versus inactivated, protein versus polysaccharide, and use
of adjuvants (10). They also include the nature of the antigen
and its intrinsic immunogenicity (11), the dose of the antigen,
the route of administration, the vaccine schedule, and the age
at administration (12). In addition, genes play a direct role in
the body’s response to vaccination even in healthy individuals
(13, 14). For each of the above determinants, there might be
a particular mechanism involved and is further influenced by
other factors including extremes of life, acute or chronic diseases,
immunosuppression, and nutrition status (12).
Early life immune responses are limited by (1) limited magni-
tude of antibody responses to polysaccharides and proteins, (2)
short persistence of antibody responses to protein, (3) influence of
maternal antibodies, and (4) limited CD8+ T cell and interferon-
gamma responses. Such factors are difficult to study in human
infants due to neonatal immune immaturity and the inhibitory
influence of maternal antibodies, which increase with gestational
age and wane a few months post-natal (7).
On the other hand, in elderly persons, the immune system
undergoes characteristic changes, termed immunosenescence,
which leads to increased incidence and severity of infectious
diseases and to insufficient protection following vaccination (15).
Vaccines induce both innate (non-specific) and adaptive (specific)
immune responses, which decline substantially with age thus
leading to the decreased efficacy of vaccines in elderly persons.
In the elderly, the innate immune response will witness a reduced
phagocytic capacity of neutrophils and macrophages, a decrease
in their oxidative burst, and impairment in the up-regulation
of MHC class II expression among other parameters (16). In
addition, persistent inflammatory processes occur with increasing
age and may reduce the capacity to recognize stimuli induced by
pathogens or vaccines. For the elderly, improved special antigen
delivery systems are needed to overcome these limitations (12).
Furthermore, the adaptive immune response is functionally
defective in the elderly. The involution of the thymus with aging
leads to a decrease in content and in output of mature naïve T
cells into the periphery, which hampers the induction of adaptive
immune responses to neoantigens. In the context of primary
vaccination, this causes reduced response rate (7–12). B cells also
undergo age-related changes that aggravate the functionality of
B cells colonies. As effector B cells accumulate, naïve B cells
decrease in number and this leads to a reduction in the diversity of
antibody responses. In brief, vaccines tailored to the needs of the
elderly will have to be developed, taking into consideration these
limitations in order to improve protection in this population.
VACCINE EFFICACY AND EFFECTIVENESS
IN THE CONTEXT OF THE
TRANSLATIONAL RESEARCH MAP
In 2010, Weinberg and Szilagyl eloquently approached the issues
of efficacy and effectiveness clarifying the road to correctly answer
the relevant but complex question: “How well does the candidate
vaccine prevent the disease for which it was developed?” They
highlighted clearly the distinction between efficacy (individual
level) and effectiveness (population level), which are often con-
fused terms that fit well into the new paradigm of translational
research (15). At about the same time, Curns et al. elaborated
on the distinction between the epidemiologic concepts of vac-
cine efficacy and effectiveness within the context of translational
research (17). Such concepts were also addressed earlier, but
slightly differently, by Clemens and co-workers in two separate
publications in 1984 and 1996, and also by Orenstein et al. in 1989
(18–20).
Accordingly, vaccine efficacy is measured as the proportionate
reduction in disease attack rate when comparing vaccinated and
unvaccinated populations. Vaccine efficacy studies always have
rigorous control for biases through randomized prospective stud-
ies and vigilantmonitoring for attack rates (15). In addition to pro-
portionate reduction in attack rates, these studies can furthermore
assess outcomes through hospitalization rates, medical visits, and
costs. Despite the complexity and expenses that arise from the
initial trials, they are needed to establish vaccine efficacy (15).
On the other hand, the related but distinct concept of vaccine
effectiveness has always been compared to a “real world” view
of how a vaccine reduces disease in a population. As such, it
can evaluate risks versus benefits behind a vaccination program
under more natural field conditions rather than in a controlled
clinical trial. Vaccination program efficiency is proportional to
vaccine potency or efficacy in addition to the degree and success
of immunization of the target groups in the population. In brief,
it is influenced by other non-vaccine-related factors that could
influence the outcome. The “real world” picture provided by
vaccine effectiveness data is desirable in planning public health
initiatives, an advantage thatmakes these studies attractive. Trans-
lating research data into real public health application are a process
that has been reengineered by the NIH as part of a road map
for future research. Consequently, a new expanded definition
of translational research, consisting of four steps was proposed,
which fits nicely within the continuum of vaccine research (21).
In this new process of phase I to phase IV clinical trials, safety,
immunogenicity, efficacy, and post-licensure effectiveness of a
particular vaccine are assessed ending up in phase IV with the
burden of the disease (15).
Vaccines stood the test of time and many techniques have
been introduced into the world of vaccination. Practitioners used
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to write articles about their vaccinating instruments and tech-
niques. According to John Kirkup, vaccinators and physicians
used various instruments and techniques to inject the vaccinating
material into the human body. More than 45 different vaccinating
instruments have been recorded in British, American, German,
and French catalogs between the years 1866 and 1920; most of
them are out of use nowadays (22).
BEGINNING OF VACCINES
There are multiple major landmarks in the history of vaccines.
It was reported that the origin goes as far back as Hippocrates,
the father of modern medicine, 400 B.C. He described mumps,
diphtheria, and epidemic jaundice among other conditions (23).
The earliest methods of immunization and protection against
smallpox date back to about 1000 A.D., and are attributed to the
Chinese. It has been said that the son of a Chinese statesman was
inoculated against smallpox by blowing powdered smallpox sores
into his nostrils (24). Another method used for inoculation was
the removal of fluid from the pustules of an infected individual
and subsequently rubbing it into a skin scratch of a healthy indi-
vidual. This procedure was later introduced into Turkey around
1672, long before reaching Europe (25). It took six centuries for
variolation to be introduced to Great Britain, in 1721 (26).
THROUGH THE EIGHTEENTH CENTURY
The eighteenth century was marked by several major events that
started with the spread of variolation from Turkey and China to
England and America, followed, in the late eighteenth century, by
Edward Jenner’s breakthrough of vaccination.
VARIOLATION FROM TURKEY TO
ENGLAND
Variolation, derived from the Latinword varus, meaning “mark on
the skin,” or inoculation, derived from the Latin word inoculare,
meaning “to graft,” are two words that were used interchangeably
in describing the aforementioned immunization process. By 1715,
variolation was introduced to England after the pursuit of an
English aristocrat, Lady Mary Wortley Montague, who had been
personally inflicted with an episode of smallpox. After being
informed of the method of variolation, she made the embassy
surgeon, Charles Maitland, perform the procedure on her 5-
year-old son in 1718 in Turkey. In 1721, Dr. Charles Maitland
performed the first English variolation on Lady Montague’s 4-
year-old daughter after their return to London (27).
LadyMontague became a great proponent of the procedure and
worked thoroughly on advocating this process for its ability to
protect against the spread of smallpox.
Data from the U.S. National Library of Medicine and the NIH
showed that 1–2% of those variolated died as compared to 30% of
those who contracted the disease naturally. Correspondingly, Rev.
CottonMather andDr. Zabdiel Boylston introduced variolation in
America andwere also great advocates of this procedure especially
since, in the same year, there was a smallpox epidemic in Boston
that killed hundreds (28). However, Lady Montague, Rev. Mather,
and Dr. Boylston faced great opposition regarding their promo-
tion of variolation even with the presentation of the comparative
analysis of fatality rates, which reached 2% for those variolated
compared to 14% for the naturally occurring disease (27).
SPREADING THE WORD
Despite some variolation-related deaths, the word of inoculation
kept spreading along with data suggesting that variolation was still
the safeguard against the spread of smallpox. In addition, Ben-
jamin Franklin, who lost his son in 1736, wrote: “I long regretted
that I had not given it to him by inoculation, which I mention for
the sake of parents who omit that operation on the supposition
that they should never forgive themselves if a child died under
it; my example showing that the regret may be the same either
way, and that therefore the safer should be chosen” (24). In 1759,
Dr. William Heberden, at his own expense and with the support
of Benjamin Franklin, wrote a pamphlet entitled “Some Account
of the Success of Inoculation for the Small-Pox in England and
America: together with plain instructions by which any person
may be enabled to perform the operation and conduct the patient
through the distemper” (29).
EDWARD JENNER’S BREAKTHROUGH
Toward the late eighteenth century came Jenner’s breakthrough
in finding a safer immunizing technique than variolation, which
is vaccination.
The method of variolation had low yet significant death rates;
therefore, physicians were on the quest of finding a new and
more secure method of immunization with minimal or no death
rates. On this basis, an English physician named Edward Jenner
(1748–1823) searched for a cure for smallpox, a debilitating dis-
ease that rendered the world helpless. Jenner became interested in
certain individuals who were immune to smallpox because they
had contracted cowpox in the past. He personally witnessed this
when he learned of a dairymaid that was immune to smallpox
due to her previous infectionwith the cowpox virus, usually trans-
mitted from infected cattle. During that time, an English farmer
named Benjamin Jesty personally took charge of inoculating his
wife and children with fresh matter from a cowpox lesion in one
of his cows out of fear of having his wife and children become
victims of the smallpox epidemic. He applied this method after
having contracted cowpox himself and believing he was immune
to smallpox. He never published his results even though his wife
and children did not show symptoms after being exposed to
smallpox (27). During these years, there were still outbreaks of
smallpox. George Washington, after surviving smallpox, ordered
mandatory inoculation for his troops in 1777 (27).
After many speculations on the role of cowpox and its immu-
nizing effect against smallpox, Jenner, in 1796, inoculated an
8-year-old boy named James Phipps using matter from a fresh
cowpox lesion on the hands of a dairymaid named Sarah Nelms
who caught them from her infected cattle. After several days,
Jenner inoculated the boy again but this time with fresh matter
from a smallpox lesion and noted that the boy did not acquire
the disease proving that he was completely protected (27). A few
years later, word of his success circulated among the public, and
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Jenner wrote “An Inquiry into the Causes and Effects of the Variolae
Vaccinae, a Disease Discovered in some of the Western Counties of
England, particularly Gloucestershire and Known by the Name of
CowPox,” after adding several cases to his initial achievement with
the boy Phipps. At first, his publication and achievement did not
stir any interest in his community, but with time, word of Jenner’s
breakthrough began spreading (27).
The late eighteenth century was characterized by the imple-
mentation of the new process of immunization, vaccination,
which required the inoculation of fresh matter from cowpox
lesions into the skin of healthy individuals.
THROUGH THE NINETEENTH CENTURY
The nineteenth century was a major landmark in the history of
vaccines since it witnessed discoveries made by Louis Pasteur,
the father of microbiology, and Robert Koch, the scientist who
discovered the germ responsible for tuberculosis (26).
VACCINATION VERSUS VARIOLATION
In the beginning of the nineteenth century, the term “Vaccina-
tion” was introduced by Richard Dunning from the Latin word
for cow “Vacca.” After becoming aware of the fact that vaccination
was more secure than variolation, several physicians initiated
movements against the use of variolation and advocated for its
eradication. Dr. Jean de Carro, for example, aided in the elimi-
nation of variolation and its substitution with vaccination. Some
of the major efforts implemented in America were initiated by
Dr. BenjaminWaterhouse, who received the vaccine from Edward
Jenner and vaccinated his own family. He later proved that they
acquired immunity when they remained asymptomatic after he
infected them with smallpox. Waterhouse worked effectively on
making vaccination universal in the U.S. Unfortunately, like any
other medical breakthrough, problems arose both becauseWater-
house aimed at making profit and the public was not ready to
implement these procedures. However, after breaking his initial
monopoly, Waterhouse accepted to share his vaccines and made
the supplies available to other physicians (24). Despite all these
efforts, smallpox epidemics continued to occur and Jenner stated
in a pamphlet that he wrote, “The annihilation of the small
pox, the most dreadful scourge of the human species, must be
the final result of this practice.” Eradication was finally achieved
176 years later. The time it took could be attributed to the fact that
Jenner did not think of the necessity of revaccination nor of the
instability of vaccines, which made them unable to handle dif-
ferent environmental conditions, including countries other than
England (30).
The late nineteenth century was distinguished by Pasteur’s
achievements that made him the father of vaccines after creating
the first laboratory vaccine. Louis Pasteur (1822–1895), a French
chemist and microbiologist, was the first to propose the “Germ
Theory” of disease in addition to discovering the foundations of
vaccination (26). He studied chicken cholera and received strains
of bacteria causing anthrax and septic Vibrio. Pasteur started his
experiments by intentionally infecting chickens by feeding them
cholera-pollutedmeals and then recording the fatal progression of
the illness. At first, Pasteur was using fresh cultures of the bacteria
to inoculate the chickens, most of which did not survive. During
that time, Pasteur had to go on a holiday, so he placed his assistant
in charge of injecting the chickens with fresh cultures. However,
his assistant accidentally forgot to perform the injections, and the
bacterial cultures were left in a medium that was exposed to room
air for about a month. Later, the attendant injected the chickens
with the now “attenuated” strain of bacteria resulting inmild, non-
fatal symptoms. Pasteur later re-injected these chickens, but this
time with fresh bacteria. To his surprise, they did not get ill. Ulti-
mately, Pasteur reasoned that what made the bacteria less deadly
was exposure to air, mainly oxygen. Pasteur used the French verb
“vacciner” during the years 1879 and 1880 to describe how he
was able to provide total body immunity through vaccination by
inoculation of an attenuated virulence which was the first vaccine
made by a human in the laboratory (31).
Pasteur also developed the anthrax vaccine in his laboratory,
not long after performing his studies on chicken cholera. In
1881, Pasteur used his own anthrax vaccine, which contained
attenuated live bacterial cultures in addition to carbolic acid,
and demonstrated that all vaccinated animals survived while the
control group died (32). During the same year, Louis Pasteur in
France and George Miller Sternberg in the U.S. almost simulta-
neously and independently isolated and grew the pneumococcus
organism. Later in 1884, Pasteur successfully fought rabies that
was endangering the European livestock by using his attenuated
rabies vaccine obtained from desiccated brain tissue inactivated
with formaldehyde, which provided immunity to dogs against
rabies in his experiments (26). He reported his success to the
Academy of Sciences in France, and a year later, he applied his
original vaccine 60 h after a 9-year-old boy was bitten several
times by a rabid dog. The boy survived after being first inoc-
ulated with the most attenuated organisms, then subsequently
with less attenuated organisms each day for 10 days (33). In
1888, the Pasteur Institute was established as a rabies treatment
center as well as an infectious diseases research and training
institute.
FROM LIVE VACCINES TO KILLED
VACCINES
After Pasteur’s successful live vaccines, a new type of vaccine was
introduced in the last few years of the nineteenth century. These
were killed vaccines, whichwere directed against three chief bacte-
rial causes of human morbidity: cholera, typhoid, and the plague.
The first cholera vaccine used to immunize humans was actually
a live vaccine developed by Jaime Ferran (1852–1929), which
provided a high level of protection during the 1884 epidemic in
Spain. However, the first killed vaccine for cholera was developed
in 1896 by Wilhelm Kolle (1868–1935) and was used in Japan in
1902 with over 80% efficiency. The credit for developing the killed
typhoid vaccine during the 1890s goes to bothRichard Pfeiffer and
Almroth Wright who made great contributions. Wright was later
credited for carrying out the “first large-scale vaccination using a
killed typhoid vaccine” (34). Finally, the killed vaccine for plague
was first developed in 1896 by Haffkine, who was one of Pasteur’s
followers, when an epidemic struck Bombay.
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LATE NINETEENTH AND TWENTIETH
CENTURY
During this period, vaccine production was taken over by factory-
type laboratories, which formed the precursors of the biological
products supply houses. Many types were produced.
TOXOID
Paul Ehrlich (1854–1915), a German physician and scientist who
worked under a contractual collaboration with Behring, noted the
existence of toxoids in the late 1890s. He also promoted enrich-
ment and standardization protocols. These protocols enabled the
exact determination of quality of the diphtheria antitoxins. In
1907, it was demonstrated that toxoids could be used to durably
immunize guinea pigs. It is crucial to briefly address the historical
background of the bacterial infections that led to some of the
earliest and most successful use of toxoids, inactivated forms
of bacterial toxins, for the purpose of immunization. Until the
twentieth century, diphtheria, tetanus, and pertussis proved to be
significant causes of illness and death with no effective treatments
or prevention in sight. Fortunately, advances in 1890 improved
the prognosis of numerous future patients (35). At the end of the
nineteenth century, especially in 1896 and 1897, the cholera and
typhoid vaccines were developed, followed by the introduction of
the plague vaccine. The latter was preceded by the preparation
of anti plague horse serum at the Pasteur Institute by Alexandre
Yersin.
Yersin demonstrated disease protection in animals. Later, he
went to China to try his vaccine on humans during a plague
epidemic (26).
DIPHTHERIA
Diphtheria is a potentially fatal disease that primarily involves
tissues of the upper respiratory tract and kills its victims slowly
by suffocation. In 1884, a German physician, Edwin Klebs
(1834–1913), was able to successfully isolate the bacteria that
proved to be the etiological agent of the disease. It was later
proved that toxin production is initiated only after the bacteria are
themselves infected by a specific virus or a bacteriophage carrying
the toxin’s genetic instructions (35).
In France, during the year 1888, Emile Roux discovered the
diphtheria toxin. His discovery led to the development of passive
serum therapies through the scientific contributions of many,
including Emil Von Behring and Paul Ehrlich (26). Similarly, the
etiological agent of Pertussis, commonly known as the “whoop-
ing cough,” was found to be a bacterium isolated from infected
patient tissues in 1906 (36). Tetanus was similarly a significant
cause of mortality usually resulting from dysfunction of the
autonomic nervous system or the respiratory muscles (37). In
1884, another German scientist, Arthur Nicolaier (1862–1942),
correlated tetanus with an anaerobic soil bacterium found in
wounds. A few years later, the Japanese investigator Shibasaburo
Kitasato (1853–1931) was able to isolate this bacterium (35). At
the beginning of World War I in 1914, the tetanus toxoid was
introduced following the development of an effective therapeutic
serum against tetanus by Emil Von Behring and Shibasaburo
Kitasato. The rabies and typhoid vaccines were then licensed in
the U.S. as the etiology of these destructive diseases was slowly
being uncovered, by Shibasaburo Kitasato along with Emil von
Behring (26). They discovered that the serum of animals that
had been exposed to sub-lethal doses of the bacteria involved in
tetanus and diphtheria was protective against the lethal effects
associated with these pathogens by having an antitoxin effect
when injected into another animal. Additionally, this discovery,
which earned Behring the inaugural Nobel Prize for Physiology
andMedicine in 1901, was the concept of passive transfer in addi-
tion to serum therapy. He proved that serum could be acquired
from immune animals and transferred to others as protection
(38). Once this concept made its way to clinical practice in 1891,
technical problemswere facedwhile developing the right antitoxin
concentration and potency. As a result, in the early twentieth
century, the U.S. Congress enacted the Biologics Control Act
legislation “to regulate the sale of viruses, serums, toxins, and
similar products” to ensure medication quality control. Neverthe-
less, with the increasing use and popularity of antitoxins derived
from animal serum, scientists began to observe a syndrome now
called serum sickness, or a reaction to immune-complexes formed
from combining high concentrations of antigens with antibod-
ies. This eventually led to the use of human rather than animal
serum in order to decrease the frequency of adverse events; still,
serum therapy was not perfect in preventing disease due to the
frequency of adverse events and its brief duration of action. Later
on, combining diphtheria toxin and antitoxin in the same syringe
proved much more effective in decreasing mortality rate. This
combination became commercially available in 1897. This was the
first step in the shift from passive to active immunization (35). In
1923, Gaston Ramon (1886–1963), a French veterinarian working
at the Pasteur Institute, used a diphtheria toxoid produced by
formalin and heat inactivation without the use of antitoxin to
safely induce active immunity in humans. This product, termed
anatoxine, was the basis for the novel and clinically effective toxoid
vaccine against diphtheria. Experiments followed to improve the
durability of the protective response of the vaccine, and in 1926,
the importance of aluminum salts as an adjuvant added to the
vaccine to augment the immune response to the antigen, became
apparent (38). This was discovered by Alexander Thomas Glenny
(1882–1965) who proved that toxoid alone produced a lower level
of antibody and immunity than desired, whereas better immunity
was achieved when an inflammatory reaction was triggered. With
these significant improvements, tetanus and diphtheria toxoids
became routinely used across America and Europe in the 1930s
and 1940s (35).
Since then, refinements have been made to these vaccines to
yield higher purity and reduce the number of booster doses.
Nowadays, widespread childhood vaccination is reducing the bur-
den of these diseases. While this is a huge advantage, vaccines
may potentially produce adverse effects that can discourage their
acceptance by some populations. This has led to numerous safety
movements which culminated in the congressionally legislated
National Childhood Vaccine Injury Act in the 1980s created to
compensate families for selected adverse events potentially related
to mandatory childhood vaccinations (37). Nevertheless, global
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recommendations continue to call for routine immunization of
children against diphtheria, tetanus, and pertussis with the com-
bined DTP vaccine to sustain immunity in childhood and adoles-
cence. DTP has, therefore, become one of the most widely used
vaccines to achieve widespread immunity across age groups (35).
TUBERCULOSIS AND BCG
Tuberculosis, otherwise known as the “Great White Plague,”
is another disease that started spreading as an epidemic once
industrialization began. This disease caused approximately 15%
of deaths in the eighteenth and nineteenth centuries across all
socioeconomic groups (39).
A French physician named Jean Antoine Villemin (1827–1892)
demonstrated that the mode of transmission of disease is through
the respiratory system. Robert Koch (1843–1910), known as
the founder of modern bacteriology, revealed in 1882 that the
causative agent of the disease isMycobacterium tuberculosis, which
later became known as Koch’s bacillus (40). Following this dis-
covery, Koch created what later came to be known as Koch’s
postulates, which listed the criteria necessary for proof of bacterial
causality: “the organism must be present in diseased tissues; it
must be isolated and grown in pure culture; and the cultured
organisms must induce the disease when inoculated into healthy
experimental animals” (39).
In 1908, two bacteriologists working in the Pasteur Insti-
tute in Lille, Albert Calmette (1863–1933) and Camile Guerin
(1872–1961), announced their discovery ofMycobacterium bovis,
which is a strain of tubercle bacilli that could be used to create a
vaccine against tuberculosis. This occurred after it became evident
that different forms of the bacterium were required to prevent
or treat tuberculosis, including non-pathogenic, attenuated, or
killed tubercle bacilli from different sources, including human,
bovine, and equine. This strain had an attenuated virulence while
maintaining its antigenicity and became known as BCG (40).
Bacille Calmette–Guerin vaccinations proved to be successful
in animal studies in 1921 and were soon used as an oral vaccine
to immunize humans against tuberculosis. In 1927, the BCG
vaccine, constituted by the live-attenuatedM. bovis, was first used
in newborns. It has become the most widely administered of all
vaccines in the WHO Expanded Program for Immunization, but
has been estimated to prevent only 5% of all potentially vaccine-
preventable deaths due to tuberculosis (26). Despite its imperfec-
tions, BCG remains the only effective vaccination for protection
against human tuberculosis (39).
YELLOW FEVER
Yellow fever is a highly fatal infection caused by a small, enveloped,
single-stranded RNA virus and results in renal, hepatic, and
myocardial injury, along with hemorrhage and shock (41). Unlike
previouslymentioned diseases, the history of yellow fever is highly
uncertain and filled with misconceptions. Early work on immu-
nization against the disease began with Carlos Finlay (1833–1915)
in the 1870s and 1880s when Koch’s postulates were becoming
increasingly accepted. Finlay proposed that mosquitos carried the
yellow fever “germ.”He attempted to prove it by feedingmosquitos
that had fed on yellow fever patients. However, it was later revealed
that his process failed due to the lack of an incubation period
within the mosquito, which is a transmission requirement that
Finlay was unaware of (42).
Since 1900, significant advances have been made in creating a
vaccine by the Yellow Fever Commission, which was originally led
by Walter Reed (1851–1902) along with Jesse Lazear, Aristedes
Agramonte, and James Carroll. Reed’s experiments took Finlay’s
discovery one step further by adding an incubation period of
approximately 2weeks and achieved the same positive results.
When mosquitos bite non-immune individuals after feeding on
individuals who had yellow fever, none of the non-immune sub-
jects died and very few suffered disease. This led the Commission
of investigators to a major discovery, namely, the identification
of the Asibi strain, which is the parent strain of the present
17D vaccine, obtained via continuous indirect passage through
the Aegypti mosquitos and direct passage through monkeys. In
addition to identifying the etiological agent of the disease, the
Commission also identified rhesus monkeys as susceptible hosts,
hence providing a means for testing future vaccine attempts. This
paved the way for Max Theiler and other Rockefeller Foundation
scientists to develop a successful live-attenuated vaccine for yellow
fever in 1937. “The most important experimental passage series –
designated 17D – used a virus that had been subcultured eighteen
times in whole mouse embryos, followed by 58 passages in whole-
minced chick embryo cultures, after which the virus was passed in
minced chick embryo depleted of nervous tissue.” Theiler himself
was actually one of the first individuals to be successfully vac-
cinated. The vaccine was quickly implemented, and alternative
vaccines shown to be more dangerous were discontinued (42).
INFLUENZA
Influenza has proved to be very difficult to trace back in history
due to its non-specific symptoms and features. It was not until the
early twentieth century that influenza outbreaks began to be sys-
tematically studied due to well-documented clinical descriptions
and epidemiological data. In 1918, the “Spanish flu” influenza
pandemic was responsible for 25–50 million deaths worldwide
andmore than one-half million in the U.S. This virus was unusual
because it spread so quickly, was so deadly (26). Richard E.
Shope (1901–1966), a physician who conducted his research in
the Department of Animal Pathology at The Rockefeller Institute
in Princeton, was the first to isolate influenza virus; a member of
the orthomyxovirus family, from a mammalian host in 1931 (43).
He was able to induce the syndrome of swine influenza in pigs
by applying respiratory secretions intranasally. He also isolated
a bacterium from the respiratory tract of infected pigs called
Haemophilus influenzae suis.When this bacterium was combined
with a filterable agent and inoculated, the pigs developed the clini-
cal manifestations of swine influenza. These two agents seemed to
act synergistically with the virus to damage the respiratory tract
hence creating the suitable environment needed for the virus to
exercise its pathological effects. In 1933, scientists from the British
National Institute for Medical Research including Christopher
Andrews, Wilson Smith, and Patrick Laidlaw successfully isolated
and transmitted the influenza virus from humans. Throughout
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this year, “Burnet has successfully cultivated the organism in chick
embryos; other influenza types had been recognized; neutralizing
antibodies had been identified and quantitated; and viral surface
glycoproteins, H and N had been described” (43).
These discoveries led scientists to introduce the inactivated
vaccine in the mid-1940s that is still used to this day (44). The
influenza A/B vaccine was initially presented to the Armed Forces
Epidemiological Board in 1942. It was licensed following the
war and used for civilians in 1945 in the U.S. Starting 1985, a
series of vaccines were licensed for Haemophilus influenza type b
(Hib) polysaccharide vaccines. These vaccines are recommended
routinely for children at 15 and 24months of age. The vaccine was,
however, not consistently immunogenic in children <18months
of age. In 1987, the protein-conjugated Hib vaccine was licensed
and in the next 2 years, it became available. During 1996, a
combined vaccine Hib conjugate and Hepatitis B was licensed.
Later on, in 2003, the first nasally administered influenza vac-
cine was licensed. This live influenza A and B virus vaccine was
indicated for healthy, non-pregnant persons ages 5–49 years. The
contracts to develop vaccine against the H5N1 avian influenza
virus were awarded to Aventis Pasteur and to Chiron in 2004.
During the following year, an inactivated, injectable influenza
vaccine was licensed. It was indicated for adults 18 years of age
and older.
During the same year, the FDA approved Afluria, a new inacti-
vated influenza vaccine, for use in people aged 18 years and older.
Two years later in 2009, the Department of Health and Human
Services, supported the building of a facility to manufacture cell-
based influenza vaccine. It also directed toward development of
a vaccine for novel influenza A (H1N1). During the same year,
the FDA approved four vaccines against the H1N1 influenza virus
high-dose inactivated influenza vaccine (Fluzone High-Dose) for
people aged 65 years and older. In 2012, the FDA approved several
vaccines: HibMenCY a new combination of meningococcal and
Hib vaccine for infants; Flucelvax, which is the first seasonal
influenza vaccine,manufactured using cell culture technology and
a quadrivalent formulation of Fluarix (26).
Unfortunately, one of the difficulties in dealing with influenza
is the continuous mutability of the viral genome necessitating
annual reassessments and reformulations of the vaccine. This has
led to a suboptimal effectiveness of influenza vaccines, which are
only successful against strains included in the vaccine formulation
or strains of homogenous subtype. Several pandemics were caused
by the influenza virus: during the years 1957–1958, The “Asian”
influenza pandemic caused by H2N2 influenza virus resulted in
an estimated 70,000 deaths in the U.S. alone and in the years
1968–1969, the “Hong Kong” influenza pandemic caused by an
H3N2 influenza virus induced roughly 34,000 deaths in the U.S.
(26). Future studies should focus on producing vaccines protective
against variant strains and creating surveillance systems to detect
novel strains in time to formulate the proper vaccines.
POLIOMYELITIS
Poliomyelitis, or Polio, is an intestinal infection spread between
humans through the fecal–oral route. It is a disease of the devel-
oped nations striking younger individuals most frequently in
warmer weather. One of the most famous polio victims, President
Franklin D. Roosevelt, founded the National Foundation for
Infantile Paralysis in 1938, later known as the March of Dimes
(26). It is well established that better hygiene decreases childhood
exposure to the disease, when infection would usually be milder
since protective maternal antibodies are present (45). In 1954, the
Nobel Prize in Medicine was awarded to John Enders, Thomas
Weller, and Fredrick Robbins for their discovery of the ability of
poliomyelitis viruses to grow in tissue cultures (26). Two major
lifelong competitors were involved in the race for the Polio vac-
cine, Jonas Salk (1914–1995) and Albert Sabin (1906–1993). Salk
took amore traditional route using a killed-virus approach, which
did not involve natural infection in acquiring immunity. Instead,
his approach involved a fully inactivated virus that still had the
ability to induce protective antibodies. Sabin, on the other hand,
set out to create a live-virus vaccine based on the belief that this
would trigger natural immunity and provide a lasting protection.
Salk had speed, simplicity, and safety on his side since a killed-
virus did not have the ability to revert to virulence, whereas the
live-virus vaccine could be given orally, establish longer lasting
immunity, and offer passive vaccination through the excreted
weakened virus potentially immunizing a large portion of non-
vaccinated communities (46).
Not surprisingly, Salk’s vaccine was the first to make it to
the population. Following successful clinical trials in 1954, six
companies began mass production of the vaccine. Unfortunately,
Salk’s vaccines were soon suspended and recalled when contam-
inated samples were found in the market due to poor monitor-
ing and control in some laboratories leading to serious health
consequences and national panic. The first Cutter polio vaccine
incidentwas reported onApril 25, 1955with 5more cases reported
just a day later with the number eventually rising to 94 of those
vaccinated and in 166 of their close contacts. OnApril 27, the Lab-
oratory of Biologics Control requested that Cutter Laboratories
recall all vaccines and the company did so immediately. On May
7, the Surgeon General recommended that all polio vaccinations
be suspended pending inspection of each manufacturing facility
and thorough review of the procedures for testing vaccine safety.
The investigation found that live polio virus had survived in two
batches of vaccines produced by Cutter Laboratories. Large-scale
polio vaccinations resumed in the fall of 1955 (26). At the same
time, Sabin had been making great advances with his live-virus
vaccine since 1951. After successful clinical trials conducted in
the Soviet Union that left polio virtually wiped out with no safety
issues, it soon became the vaccine of choice in theWest. The Polio
Vaccination Assistance Act was enacted by Congress and was the
first federal involvement in immunization activities. It allowed
Congress to appropriate funds to the Communicable Diseases
Center [later the Centers for Disease Control and Prevention
(CDC)] to help states and local communities acquire and admin-
ister vaccines. At the beginning of the 1960s, the oral polio vaccine
types 1, 2, and 3 as well as the trivalent product were licensed in
the U.S. The first 2 were developed by Sabin and grown inmonkey
kidney cell culture, while the trivalent oral polio was developed
to improve upon the killed Salk vaccine (26). As a result, in the
late 1990s, the CDC recommended switching back to Salk’s killed-
virus polio vaccine, while the WHO also advocated the switch for
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polio-free nations and the continued use of the favored live-virus
vaccine for routine immunization (45).
The last two cases of wild type polio were reported in an
unvaccinated Amish in 1979 and in a 5-year-old boy from Peru in
1991 (26). In 1990, the enhanced-potency inactivated poliovirus
vaccine was licensed.
MEASLES, MUMPS, AND RUBELLA
Following successful developments in the polio vaccine, attention
soon shifted to three other common viral diseases of childhood:
measles, mumps, and rubella.
The measles virus is an RNA virus from the genusMorbillivirus
belonging to the Paramyxooviridae family. It causes an acute
illness that includes fever, cough, malaise, coryza, and conjunc-
tivitis, in addition to a maculopapular rash. In general, measles
is a mild disease but, like many others, has the potential to
cause serious complications. In addition, measles is known to
be one of the most contagious human diseases causing major
outbreaks to occur very often. Until the year 2000, measles was
still the leading cause of vaccine-preventable childhood deaths
worldwide (47).
John Enders (1897–1985), known as the “Father of Modern
Vaccines” had a particular interest in revealing the virus respon-
sible for measles. He isolated the Edmonston strain of the virus
in 1954, which was named after the child from whom it was
isolated. A formalin-inactivated measles virus vaccine derived
from this strain was subsequently licensed in the U.S. in 1963.
However, following the discontinuation of this vaccine in 1967
due to short-lived and incomplete immunity, over 20 further
attenuated vaccines were developed and used throughout the
world, most of which were also derived from the Edmonston
strain (48). The first live-virus measles vaccine, Rubeovax, was
licensed in 1963. Other live-attenuated virus measles vaccines
were eventually licensed in the U.S. in 1965. The recommended
age for routine administration was changed from 9 to 12months
of age.
The first national measles vaccine campaign was launched in
1966. The world recorded a 90% decreased incidence compared
to the pre-vaccination years. In 1968, a second live, further atten-
uated measles virus vaccine was also licensed. In 1989, both the
Advisory Committee on Immunization Practices (ACIP) and the
American Academy of Pediatrics (AAP) issued recommendations
for a routine second dose of the measles vaccine. During the mid-
to-late 1980s, a high proportion of reported measles cases were
in school-aged children (5–19 years) who had been appropriately
vaccinated. These vaccine failures led to new national recommen-
dations of a second dose of measles-containing vaccine (26).
Mumps is another acute viral illness. It is the only virus known
to cause epidemic parotiditis in humans accompanied by fever,
anorexia, headache, and malaise. K. Habel and John Enders iso-
lated the virus in 1945 (26), and trials of formalin-inactivated
mumps vaccine in humans began the same year by Joseph Stokes
and colleagues and by Enders. This approach was abandoned in
the 1950s due to short-lived immunity, and work began to develop
live-attenuatedmumps vaccines in 1959 by the vaccinologistMau-
rice Hilleman (1919–2005) and colleagues (48). Hilleman isolated
the wild type virus from his daughter, Jeryl Lynn, who contracted
the virus at the age of 5 and was recovering from it. It became
known as the Jeryl Lynn strain of mumps virus. The mumps live-
virus vaccine was licensed in December 28, 1967 (26). Trials with
this attenuated virus resulted in 100% protective efficacy and the
vaccine was licensed in the U.S. in 1967. This strain is still used to
produce mumps vaccines until this day. It is given as part of the
measles, mumps, and rubella (MMR) vaccine (49).
Rubella is a rash disease in children and adolescents caused
by a filterable virus. It poses a severe threat to pregnant women
and their children by potentially causing congenital deafness and
cataracts. In 1964, a rubella epidemic swept the U.S. resulting in
12.5 million cases of rubella infection, with an estimated 20,000
newborns having congenital rubella syndrome (CRS), along with
fetal and neonatal deaths in the thousands (26). The rubella virus
was detected and isolated by two groups of scientists, Thomas
Weller and Franklin Neva at Harvard Medical School, in addition
to Paul Parkman and colleagues at theWalter Reed Army Institute
of Research (WRAIR). Similar to measles and mumps, inacti-
vated whole virus vaccines proved ineffective, so efforts turned to
discovering a live-attenuated vaccine (26).
In 1963, Paul Parkman left WRAIR and joined Harry Meyer
Jr. at the NIH Division of Biological Standards, and the pair
developed the first live-attenuated rubella vaccine in 1966, HPV-
77, which was subsequently included in the initial MMR vaccine
used in the U.S. in the 1970s (26). Maurice Hilleman discovered
the superior RA 27/3 vaccine that became the only vaccine used
outside of Japan starting in the late 1970s. This vaccinemaintained
its preference due to many factors including increased durability
and harmlessness to fetuses of inadvertently vaccinated pregnant
women (47). In 1969, three rubella virus strains were licensed
in the U.S.: HPV-77 strain grown in dog-kidney culture, HPV-
77 grown in duck-embryo culture, and Cendehill strain grown
in rabbit-kidney culture. A decade later, in 1979, the RA 27/3
(human diploid fibroblast) strain of rubella vaccine (Meruvax
II) by Merck was licensed. All other strains were discontinued.
Merck’s combined trivalentMMR as well as the combinedmeasles
and rubella vaccine (M-RVax) developed by Maurice Hilleman
and colleagues, was licensed by the U.S. government in 1971 (26),
and is still in use today. Moreover, the age for routine vaccination
with MMR vaccine was changed from 12 to 15months in the
year of 1976. The next vaccine that combined measles, mumps,
rubella, and varicella antigens (Proquad) was licensed in 2005.
It was indicated for use in children 12months to 12 years. In
response to the association of this vaccine with autism, in 2004,
the eighth and final report of the Immunization Safety Review
Committee was issued by the Institute of Medicine concluded
that the body of epidemiological evidence favors rejection of a
causal relationship between the MMR vaccine and autism (26).
Combination vaccines hold many advantages including reduced
need for several injections, therefore, reducing the incidence of
vaccination site reaction (48).
HEPATITIS
The etiological agent of clinical hepatitis, identified by its dis-
tinguishing yellow jaundice, was found to be infectious in the
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early 1900s. The different hepatitis strains, A and B, were first
differentiated in 1942 (26). In the mid-1960s, Blumberg and co-
workers and Prince discovered hepatitis B surface antigen in the
circulating blood of carriers of the infection. Deinhardt et al. soon
followed this discovery with that of the hepatitis A virus (49).
Provost et al. successfully prepared a killed hepatitis A vaccine in
1986, which proved to be safe and highly effective in extensive
clinical trials. The first inactivated hepatitis A vaccine (Havrix)
was licensed in 1995. The following year, a second inactivated
vaccine (Vaqta) also became available (50).
Hepatitis B, on the other hand, rarely causes any severe risk
as a primary infection. However, those who develop a chronic
persistent infection may continue to have severe disease for
the rest of their lives. This may even lead to cirrhotic destruc-
tion of the liver due to host immune response to the virus.
The discovery of the surface antigen particles of the hepatitis
B virus by Blumberg and colleagues in the plasma of human
carriers was followed by attempts to create a vaccine. In 1968,
a killed hepatitis B vaccine was developed and clinical tri-
als began in 1975 proving the safety and efficacy of the vac-
cine. Merck and Pasteur Institute subsequently independently
licensed the plasma-derived vaccine in 1981 (50). On July 23rd
1986, the recombinant hepatitis B vaccine (Recombivax HB)
was licensed. Using recombinant DNA technology, Merck sci-
entists developed a hepatitis B surface antigen subunit vaccine.
Three years later, on August 28th 1989, the recombinant hep-
atitis B vaccine (Engerix-B) was licensed. A decade later in
1999, the FDA approved a two-dose schedule of hepatitis B
vaccination for adolescents 11–15 years of age using Recom-
bivax HB (by Merck) with the 10-μg (adult) dose at 0 and
4–6months later. At the beginning of the new millennium, in
2001, a combined hepatitis A inactivated and hepatitis B (recom-
binant) vaccine, Twinrix was licensed. The following year, a
vaccine combining diphtheria, tetanus, acellular pertussis, inac-
tivated polio, and hepatitis B antigens (Pediarix) was licensed
(26). In conclusion, fortunately, both hepatitis A and B are now
preventable due to the discovery of these highly effective vac-
cines that proved to maintain long-term immunity in vaccinated
individuals (50).
MID TWENTIETH AND TWENTY-FIRST
CENTURY
In 1966, the World Health Assembly called for global smallpox
eradication, which was launched the following year. During the
first year of the program 217,218 cases of polio were reported
in 31 countries that were endemic to smallpox. Four years later,
the CDC recommended discontinuation of routine vaccination
for smallpox in the U.S. following a greatly reduced risk of dis-
ease (26).
During the 70s, especially in 1974, the Expanded Program on
Immunization was created within WHO, in response to poor
immunization levels in developing countries (<5% of children
in 1974). The following vaccines were used by the Expanded
Program on Immunization: BCG, Polio, DTP, measles (often
MMR vaccine), yellow fever (in endemic countries), and hepatitis
B. Three years later, in October 1977, the last case of naturally
acquired smallpox occurred in the Merca District of Somalia.
In the same year, the first pneumococcal vaccine was licensed,
containing 14 serotypes (of the 83 known serological groups) that
composed 80% of all bacteremic pneumococcal infections in the
U.S. (26).
On May 8 1980, the World Health Assembly declared the
world free of naturally occurring smallpox. On the other hand, in
July 1983, two enhanced pneumococcal polysaccharide vaccines
(Pneumovax 23 and Pnu-imune 23) were certified. These vaccines
included 23 purified capsular polysaccharide antigens of Strep-
tococcus pneumoniae and replaced the 14-valent polysaccharide
vaccine licensed in 1977. A few years later, in 1988, the World
Health Assembly passed a resolution to eradicate polio by the
year 2000 (26). Later on, in 1992, the Japanese encephalitis (JE)
inactivated virus vaccine (JE-Vax) was licensed.
During the year 1994, The Expanded Program for Vaccine
Development and the Vaccine Supply and Quality Program were
merged creating the Global Program for Vaccines and Immuniza-
tion. During the same year, the Western Hemisphere was finally
labeled as “polio-free” by the International Commission for the
Certification of Polio-Eradication.
The 1996 was another monumental year with the launch-
ing of the International AIDS Vaccine Initiative (IAVI) that
called for the speedy development of a human immunodefi-
ciency virus (HIV) vaccine for use worldwide. This in turn
led to the introduction of the Scientific Blueprint for AIDS
Vaccine Development. IAVI was funded by several NGOs and
foundations. It is a Collaborating Center of the Joint United
Nations Program on HIV/AIDS (UNAIDS) whose efforts led
finally lead to the first possible vaccine against HIV (Aidsvax)
which reached Phase III trials, the largest recorded human
HIV vaccine trial at that time. The trial involved 5400 volun-
teers from the U.S., Canada, and the Netherlands, the major-
ity of whom were men who have sex with men (26). Prelim-
inary results from the trial of AIDS VAX (VaxGen) vaccine
were reported in early 2003. While the vaccine was shown
to be protective amongst non-Caucasian populations, especially
African-Americans, the same effect was not reproducible in Cau-
casians (26).
During the same year, the Children’s Vaccine Program was
established at WHO’s Program for Appropriate Technology in
Health (PATH). The program’s goal was to provide vaccines to
children in the developing world and to accelerate research and
development of new vaccines. The first vaccines purchased were
Hib, Hepatitis B, Rotavirus, and Pneumococcal, which were not
commonly used in the developing world (26).
At the beginning of the new millennium, the Western Pacific
Region of the world was certified as polio-free. During the next
2 years, the European Region also became certified as polio-free.
In 2006, the FDA licensed the first vaccine developed to prevent
cervical cancer (Gardesil), precancerous genital lesions and geni-
tal warts due to human papillomavirus (HPV) types 6, 11, 16, and
18. The first smallpox vaccine for certain immune-compromised
populations was delivered under Project BioShield on July 10th
2010. The following year 2010, the WHO declared the “Decade of
Vaccines” and in 2012, the United Nations Foundation launched
Shot@Life campaign (26).
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VARICELLA ZOSTER: HERPES VIRUS
Varicella (“chickenpox”) is caused by the varicella zoster virus
(VZV). Michiaki Takahashi, Professor of Virology at the Research
Institute for Microbial Diseases at Osaka University, successfully
produced the Oka vaccine strain of live, attenuated varicella vac-
cine in the 1970s. Takahashi was able to make this remarkable
advance at a time when very few viruses had been attenuated
to produce efficacious live-virus vaccines including yellow fever,
polio, measles, mumps, and rubella as previously mentioned.
The VZV vaccine is the first and only licensed live, attenuated
herpesvirus vaccine in the world. Numerous trials in the early
1970s continued to prove the safety and efficacy of the vaccine
in both healthy and immunocompromised, high-risk individuals.
As a result of these successful trials, the live varicella virus vaccine
(Varivax) was licensed in 1995 for the active immunization of
persons 12months of age and older (51). About 10 years later, in
2006, VariZIG, a new immune globulin product for post-exposure
prophylaxis of varicella, became available under an Investigational
New Drug Application Expanded Access Protocol (26).
As a herpesvirus, VZV possesses the unique ability to establish
latent infection subsequent to primary infection. Zoster results
from reactivation of latent VZV that spreads through nerves to
the skin. Therefore, one fear associated with this vaccination was
the possibility that it could increase the incidence and/or severity
of zoster when compared to natural disease. Conversely, it was
actually shown that following vaccination, zoster is less common
than after natural infection (51). In 2006, the FDA licensed a new
vaccine to reduce the risk of shingles in the elderly. The vaccine,
Zostavax was approved for use in people aged 60 years of age and
older (26).
ROTAVIRUS
Rotavirus is the leading cause of severe diarrhea and vomiting
(severe acute gastroenteritis) among young infants and children
worldwide. No significant difference was found in the incidence
of rotavirus in industrialized and developing countries, suggesting
that vaccination may be the only way to control the impact of
this severe disease. Dr. Ruth Bishop and colleagues were the first
to describe rotavirus in humans in 1973. It was clear, early on,
that a naturally acquired first infection, whether symptomatic or
asymptomatic, was the most effective defense against severe rein-
fection, and subsequent infections progressively created greater
protection. Therefore, the goal was to create a vaccination that
mimicked the effectiveness of naturally acquired immunity fol-
lowing infection. The development of live, attenuated, oral, safe,
and effective rotavirus vaccines was then attempted starting in
the mid-1970s. Dr. Albert Kapikian and colleagues, at the NIH,
developed the RRV strain that was subsequently used to develop
the RRV-TV, or the RotaShield, live oral, and tetravalent vaccine
licensed in 1998 to be used in infants at 2, 4, and 6months of age
(26). However, due to several reported cases of vaccine-associated
intestinal intussusception, RotaShield was pulled off themarket in
the U.S. 14months after its introduction on the 16th of October,
1999. In 2004, the National Institute of Allergy and Infectious
Diseases (NIAID), part of the NIH, awarded a new license agree-
ment for RotaShield to BIOVIRx, Inc. of Minneapolis, MN, USA,
which planned its global commercialization. In 2011, history of
intussusception was added as a contraindication for rotavirus vac-
cination (26). Clark, Offit, and Plotkin then produced the RotaTeq
vaccine byMerck based on their bovine strainWC3 in 1992, which
was licensed in 2006 by the U.S. FDA. This vaccine, live oral and
pentavalent, is destined for use in infants ages 6–32weeks (26).
Another vaccine, Rotarix, was also licensed in 2008. It is a liquid
given in a two-dose series to infants from 6 to 24weeks of age.
Before being licensed, both vaccines were shown to be safe and
effective in rigorous clinical trials (52).
RESPONSE TO EMERGING DISEASES IN
THE TWENTY-FIRST CENTURY
During the past two decades, improvements in environmental
health have contributed tremendously to disease vector control.
However, substantial challenges remain in dealing with the newly
emerging diseases such as severe acute respiratory syndrome
(SARS), H1N1, H7N9, and H5N1 influenza, middle east respira-
tory syndrome (MERS-CoV), rotavirus, Ebola virus, and a variety
of other viral, bacterial, and protozoal diseases (53).
The role of vaccines in the control and protection from
the above mentioned emerging diseases cannot be overempha-
sized. Actually, the importance of inducing protective immunity
through vaccination came out to be the most powerful tool and
effective strategy to prevent the spread of emerging viruses among
populations, in particular, among people that are immunolog-
ically naïve and susceptible hosts. Such emerging diseases rep-
resent a major public health concern; they affect livestock and
humans thus threatening the world’s economy and public health.
Vaccine strategies for emerging pathologies are limited by sudden
appearance of the pathogen and the delayed time consuming tra-
ditional vaccine development process. Novel methods to rapidly
develop vaccine are being experimented, whereby investigators
are working to achieve a better understanding of the nature of
the interactions between the immune system and a panel of novel
harmful microbes. On this basis several novel strategies have been
developed and applied. Such strategies included the use of (1)
recombinant proteins, or nanoparticles like in SARS-CoV and
MERS-CoV, (2) synthetic peptides like the case of influenza virus,
(3) virus-like particles, (4) multimeric presentation of viral anti-
gens like the case of Hepatitis, (5) replication of competent viral
vectors like in the Rift Valley Fever virus or the EBOLAviruses, (6)
recombinant bacteria for Listeria and Salmonella among others,
and (7) nucleic acid vaccines for EBOLA or Dengue or Rift Valley
Fever viruses (54).
In managing or even in preventing the emergence of new
infectious diseases, a plan should be developed to strengthen
surveillance and promote a multi-partners response within local,
national, and global programs.
With the high burden of emerging infectious diseases (EID) it
becomes an essential part to find an effective method of either
preventing or controlling their spread, that is where the role
of vaccines prevails. It is significant to mention that the aver-
age case fatality rate for Ebola is around 50% and outbreaks
are affecting both developed and developing countries. Another
emerging disease, MERS-CoV, has caused the death of around
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TABLE 1 | Development, introduction, infectious agent, schedule, and efficacy of vaccines.
Vaccine (year introduced) Infectious agent Kind of vaccine
first introduced
Vaccine used in present Time for vaccination Need of booster Efficacy
Smallpox (1798) Variola virus Live vaccinia virus N/A Stopped in 1972 after eradication N/A Global eradication
Anthrax (1881) Bacillus anthracis Live, attenuated Cell-free filtrates of
microaerophilic cultures of a
toxigenic, non-encapsulated
strainof B. anthracis
V770-NP1-R
Pre-exposure in adults 18 years
old; 5 shots over 18months
Yes; annually 92.50%
Rabies (1884) Rabies virus Live, attenuated Inactivated virus Post-exposure; 4 doses (0, 3, 7, 14) Not recommended Inconclusive data
Typhoid (1896) Salmonella typhi Inactivated Inactivated; live, attenuated At risk population; inactivated: one
dose; live, attenuated: 4 doses every
other day
Yes if at risk; inactivated:
every 2 years; live,
attenuated: every 5 years
Varies with age; >50%
Cholera (1884–1896) Vibrio cholerae Live, attenuated Oral, inactivated, killed
whole cell of V. cholerae
At risk population; 2 doses 1week
apart
Yes if at risk; every 6months 50–60%
Tuberculosis (1927) Mycobacterium
tuberculosis
Live, attenuated
Mycobacterium bovis
N/A Single dose for children Not recommended 70–80%
Yellow fever (1935) Yellow fever virus Live, attenuated Live, attenuated Single dose 9months old Not recommended Long term (80–100%)
Diphtheria and tetanus
toxoids (1930s and 1940s)
and acellular pertussis (dtap)a
(1948)
Corynebacterium
diphtheria, Bordetella
pertussis, Clostridium
tetani
Inactivated Inactivated 2, 4, 6, 15–18months, 4–6 years Yes; Tdap: 11–12 years; If
Tdap not received between
11–18 years, Tdap dose
should be given then
followed with Td booster
doses every 10 years
80–85%
Poliovirus (1955) Poliovirus Inactivated poliovirus Inactivated and oral, live
attenuated
2, 4, 6–18months Yes; 4–6 years IPV: 99%
OPV: >95%
Influenza (1954–1955) Influenza virus Inactivated Inactivated and live
attenuated
Annually Not recommended Inactivated: 60% Live
attenuated: >87%
Measles, Mumps, Rubella
(1971)
Measles, mumps, rubella Inactivated Live, attenuated 12–15months, 4–6 years Not recommended >95%
Meningococcal (1974) Neisseria meningitidis Polysaccharide Conjugate 11–12 years Yes; 16 years >85%
Pneumococcal (1977) Streptococcus
pneumoniae
Polysaccharide Polysaccharide-protein
conjugate
2, 4, 6, 12–15months Yes; if at risk, 65 years old Children: >90%; adults
>65: 75%
Hepatitis B (1981) Hepatitis B virus Plasma derived DNA recombinant 0, 1–2, 6–18months Not recommended Long term (80–100%)
Haemophilus influenzae
type b (Hib) (1985)
Haemophilus influenzae
type B
Polysaccharide Polysaccharide-protein
conjugate
2, 4months Yes; 12–15months 95–100%
Japanese Encephalitis (1992) Japanese encephalitis
virus
N/A Inactivated virus Endemic countries: two-dose series
28 days apart
Yes; if risk of exposure No data available
Varicella (1995) Varicella zoster virus Live Live, attenuated 12–15months, 4–6 years Not recommended >70%
Hepatitis A (1995) Hepatitis A virus Inactivated Inactivated, whole virus Two-dose series 6months apart:
12–23months old
Not recommended 94–100%
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36% of people reported to have contracted the disease. Another
disease with high health and economic burden would be rotavirus
which was estimated to have annual direct and indirect costs of
around $1 billion with “more than 400,000 physician visits, more
than 200,000 emergency department (ED) visits, 55,000 to 70,000
hospitalizations, and 20 to 60 deaths each year in children younger
than 5 years” (CDC, 2015). These are few of the facts regarding
the affliction of EID most of which have no approved vaccine yet.
On the other hand, the influenza virus which was estimated to
cause an average of 23,607 deaths annually with a $12 billion cost
of an epidemic, showed that with the introduction of its vaccine,
studies proved it to be 80% effective in preventing death (55).
These figures have managed to influence many governmental
and non-profit organizations to intervene either through govern-
mental funding of vaccines where the congress provides yearly
international EID funding to several U.S. governmental agencies
or through international non-profit organizations which are the
leaders in global health innovation (56).
DISEASE BURDEN: DIFFERENT
INFLUENTIAL ASPECTS
Vaccines remain among the most reliable and effective medical
interventions in providing the means to fight debilitating and
preventable diseases thus ensuring the continuity of mankind
and saving lives. Through reviewing the factsheets provided by
the World Health Organization, which provide statistical data
on the mortality and morbidity percentages before and after the
introduction of the vaccines, one can comprehend the vital role
vaccines have played up till this day. Some of the figures that
depict the impact of vaccines in decreasing mortality and mor-
bidity include more than 99% decrease in Polio cases since 1988,
with cases reaching 350,000 from over 125 endemic countries
down to 359 cases as reported in 2014 with only 2 endemic
countries, measles vaccine has prevented the death of around
15.6 million children during 2000–2013, in general vaccines pre-
vent around 6 million deaths annually worldwide (57). This
success in providing better public health does not negate the
economic burden of vaccination. Vaccination programs require
excessive funding to ensure proper handling and maintenance of
vaccines, adequate staffing and ongoing provision over efficacy
and safety of vaccines and the development of newer vaccines
(58). Nevertheless, the economic and social burden related to
the expenses in hospitalizing affected unvaccinated people still
outweighs the aforementioned burden. Moreover, better health
in the society would promote economic growth and produc-
tivity. Consequently, public awareness and public efforts agree
on the importance of vaccination and the implementation of
policies regarding mandatory vaccinations as a way to decrease
outbreaks of preventable diseases and improve global health and
prosperity.
TURNING POINT: VACCINE
CONTROVERSIES
As early as the introduction of vaccines, campaigns against vacci-
nation were raging. As with any new medical intervention there
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TABLE 2 | Development, introduction, infectious agent, schedule, and efficacy of potential new vaccines.
Potential new
vaccines (phase)
Infectious agent Vaccine used Time for vaccination Need of
booster
Efficacy
RTS,S/AS01 malaria vaccine
(Phase III)
Plasmodium falciparum Malarial circumsporozoite (CS)
protein
Children (5–17months) and
young infants (6–12weeks);
3 doses (months 0, 1, 2)
Yes; month 20 36.30%
Human hookworm vaccine
(Phase I)
Nematode parasites Necator
americanus and Ancylostoma
duodenale
Recombinant Na-GST-1
(N. Americanusglutathione
S-transferase-1) protein
18–45 years old; 3 doses at
56 days intervals
N/A N/A
Ebola and Marburg vaccine
(Phase I)
Ebola and Marburg viruses Ebola DNA plasmid and Marburg
DNA plasmid
18–50 years old; on weeks 0,
4, and 8
N/A N/A
GBS Vaccine (Phase II) Group B Streptococcus Polysaccharide capsules from
serotypes Ia, Ib, and III of the
Group B Streptococcus
Females 18–40 years old N/A N/A
HIV vaccine (Phase I) Human immunodeficiency virus Recombinant gp120 18–50 years old; at months 0,
1, 3, and 6
N/A N/A
Leishmania Vaccine (Phase III) Leishmaniasis parasite Autoclaved Leishmania proteins 16–60 years old; 2 doses
30days apart
N/A N/A
MERS-cov Vaccine (Phase II) Middle East respiratory
syndrome coronavirus
Purified coronavirus spike protein
nanoparticles
N/A N/A N/A
Souce: Ref. (63).
are safety concerns that arise which might be deleterious to the
public health. Concerns regarding vaccines often follow a path
that starts with the hypothesis of a potential adverse event that is
impulsively announced to the public without having reproducible
studies to confirm this hypothesis, and thus it would take the
public several years to regain trust in the vaccine. A notable
example in the recent history would be of the paper published
by AndrewWakefield in the British medical journal the Lancet in
1998, linking the MMR vaccine to autism. However, his research
was discredited and the paper was retracted from the journal
after it was proven that actually there is no link between MMR
vaccine and autism as per the systemic review by the Cochrane
library (59). The battle against vaccines did not reach a halt,
and there are still ongoing campaigns that come from religious,
political, community-based, and even individual-based grounds
raising even ethical issues regarding the mandatory vaccinations
proposed by the government. According to the CDC, this year
95% of the children were vaccinated in the U.S., leaving 5%
unvaccinated due to religious and philosophical exemptions or
even parental refusal due to the fear of vaccine’s side effects and
concerns regarding autism from vaccines (60); this is still a critical
number since the unvaccinated would pose risk of outbreaks even
among the immunized, which necessitates the need for additional
awareness campaigns regarding the importance of vaccination
since vaccines remain the only plausible measure of protection
against preventable diseases. Actually, a trend was reported in
the health news lately, in the U.S., that pediatricians refuse to
offer medical care for children whose parents declined their
vaccination.
CONCLUSION
Vaccination has been of great importance throughout centuries
(Tables 1 and 2). People started with inoculation techniques
dating back to 1000 A.D. with the Chinese, Turks, and Asians.
With every century and with every curious physician, inocula-
tion techniques improved gradually giving rise to newer vac-
cination techniques with Edward Jenner and later on, Louis
Pasteur and others. However, there is still plenty of room for
improvement with the presence of ongoing epidemics and the
spread of newly emerging diseases. One important goal is to
strengthen the science base for vaccine development and for
public health action and disease prevention. Despite the com-
mon belief that infectious diseases were virtually eliminated
by the middle of the twentieth century, new and reemerging
infections are appearing along with drug resistant infections in
the past two decades in the various parts of the world and
whose incidence threatens to increase in the near future, due
to changes in human demographics and behavior, immigration,
and speed of international travel among other things (61–63).
The importance of vaccine safety continued to grow through-
out the twenty-first century, with the development and licen-
sure of new vaccines added to the already robust immunization
armamentarium. Scientists also perfected new ways of admin-
istering immunizations including edible vaccines and needle-
less injections. However, formulated or delivered, vaccines will
remain the most effective tool we possess for preventing disease
and improving public health in the future. Despite the anti-
vaccination campaign and the association of vaccines with some
side effects, vaccines continue to remain a cornerstone in global
health.
The distinctions between national and international health
problems are losing ground and could be misleading, the “world
is a village.” Clinicians and public health workers need to interact
on regular basis with veterinarians and veterinary public health.
Actually, good examples of the necessity of such collaboration is
the emergence of SARS-CoVandMERS-CoV, it shows clearly how
coronaviruses can spillover from animals into humans at any time,
causing lethal diseases. Foodborne diseases could lead to regional
and international outbreaks which might constitute a threat to
national and global security.
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